Early pediatric anthracycline cardiotoxicity: managed by serial heart and bone marrow transplantation.
We report a favorable outcome in a child who underwent cardiac transplantation for severe early post-anthracycline-induced cardiomyopathy, 9 months after completion of treatment for acute myeloid leukemia (AML). The child suffered a relapse of AML 2 months after cardiac transplantation and then underwent a successful bone marrow transplant. This case is unique in the literature. We believe it offers an alternative strategy for children with hematologic malignancies, where severe early post-anthracycline cardiotoxicity might preclude bone marrow transplantation.
Mangat
Jasveer S
JS
Department of Paediatric Cardiology, Great Ormond Street Hospital, London, UK. jasveer_mangat@yahoo.com
Rao
Kanchan
K
Kingston
Judith
J
Veys
Paul
P
Amrolia
Persis
P
Burch
Michael
M
D018943:Anthracyclines / Q000633:toxicity*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016026:Bone Marrow Transplantation; D002648:Child; D016027:Heart Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D010198:Pancytopenia / Q000209:etiology; D012008:Recurrence; D017741:Survivors
D018943:Anthracyclines